Skip to main content Back to Top

Drug Pricing’s New Frontier – The Inflation Reduction Act

Broadcast Date: May 20, 2024


Subscribe on iTune Podcasts
Listen on Google PlaySubscribe to Stitcher Podcasts Listen on Spotify Subscribe to TuneIn PodcastsSubscribe to iHeartRadio

This podcast will provide members an overview of the Inflation Reduction Act’s drug pricing provision. We’ll cover the negotiated pricing, drug rebates, and what all of these changes will mean for you.

Jillanne Schulte Wall Jillanne Schulte Wall, JD, (she/her) is the senior director of health & regulatory policy for the American Society of Health-System Pharmacists (ASHP) in Bethesda, MD. She serves as ASHP’s primary liaison to federal regulatory agencies and, in conjunction with other members of the Government Relations team, develops and communicates of ASHP’s positions on federal and state laws, regulations, and guidance related to the profession of pharmacy.  Additionally, Jillanne works closely with stakeholders in pharmacy, medicine, manufacturing, and patient advocacy on legislative and regulatory issues of importance to ASHP members. 

Tom KrausTom Kraus, JD, (he/him) is vice president for government relations at ASHP. He is a graduate of University of Michigan (BS Biology), Georgetown University Law Center (Doctor of Law), and The Johns Hopkins University (MHS, Health Policy). Tom previously served as the chief of staff and associate commissioner for legislation at the U.S. Food and Drug Administration. He was also a senior policy advisor to Sen. Ted Kennedy and Sen. Tom Harkin on the Senate Health, Education, Labor and Pensions Committee, where he served as Deputy Staff Director for Health. 

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.  
ASHP 2020 Summer Sessions

ASHP Pharmacy Futures 2024

Welcome to our new format!
Start Here
Link the whole card

Drug Shortages

Your first stop for information and resources on drug products, their availability, and management
Learn More
Link the whole card